https://www.thebodypro.com/category/didanosine-videx-ddi

Didanosine (ddI, Videx)

The Latest

Liver

Safety Risk Associated With HIV Drug Videx

A rare but serious liver disorder has been reported in some patients taking the HIV drug Videx (didanosine) and its delayed-release formulation, Videx EC, the Food and Drug Administration (FDA) said Monday. FDA said 42 cases of non-cirrhotic portal ...

Videx EC/Videx (Didanosine) Label Change Reflects Potential for Serious Liver Disorder

The Food and Drug Administration (FDA) is alerting healthcare professionals and patients about a rare, but serious, complication in the liver known as non-cirrhotic portal hypertension in patients using Videx or Videx EC (didanosine). Didanosine is a...

Important Changes to Videx (Didanosine) Labeling

FDA recently approved new labeling for Videx pediatric powder and Videx EC capsules. The revisions to the Dosage and Administration, Contraindications, Warnings and Precautions, and Drug Interactions sections in both package inserts are outlined belo...

Cardiovascular

Abacavir, Didanosine Associated With Higher Heart Attack Risk, D:A:D Study Finds

One of the most talked-about studies presented at CROI 2008 was authored by Caroline Sabin and colleagues on behalf of the large, international D:A:D cohort.1 It focused on the impact of specific antiretrovirals on heart attack risk in HIV-infected p...

Cardiovascular

Increased Risk of Myocardial Infarction Associated With Abacavir and ddI

A poster presented by Caroline Sabin from the Royal Free Hospital looked at whether nucleoside analogues were associated with cardiovascular disease (CVD) seen in the large international D:A:D cohort study.1 D:A:D includes over 33,000 patients from 1...

FDA Approves Generic Formulation of Didanosine (ddI) Delayed Release Capsules

The Food and Drug Administration (FDA) today (December 3, 2004) approved a generic formulation of Didanosine (ddI) Delayed Release capsules, 200 mg, 250 mg, and 400 mg for use in combination with other antiretroviral agents in the treatment of HIV-1 ...

Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir

Dear Health Care Professional, Gilead Sciences, Inc. (Gilead) is writing to inform you of a high rate of early virologic failure and emergence of nucleoside reverse transcriptase inhibitor (NRTI) resistance-associated mutations observed in a clinica...

A Comparison of AZT/3TC vs. d4T/ddI, Plus Efavirenz, Nevirapine or Indinavir/Ritonavir

Controversy still exists regarding which is the best antiretroviral therapy (ART) to start with. We all agree that the regimen must be potent, safe, well tolerated, convenient for the individual, and must demonstrate both efficacy and durability. An...

New Questions About an Old Combination -- ddI + d4T

For the last several years, the combination of ddI (didanosine, Videx) and d4T (stavudine, Zerit) as a backbone of three-drug therapy has been popular both in treatment and in research. Together, the two nucleoside analog reverse transcriptase inhibi...

Thailand: Patients, Advocates Sue to Invalidate Videx EC Patent

In an effort to gain cheaper HIV/AIDS treatment for Thailand's estimated 1 million people living with the disease, patients and consumer activists on Wednesday filed a lawsuit to invalidate a drug patent held in Thailand by U.S. pharmaceutical giant ...